Literature DB >> 2168301

Severe chronic EBV infection associated with specific EBV immunodeficiency and an EBNA+ T-cell lymphoma containing linear, EBV DNA.

V R Bonagura1, B Z Katz, B L Edwards, D J Valacer, P Nisen, E Gloster, R Mir, P Lanzkowsky.   

Abstract

A patient with severe chronic Epstein-Barr virus (EBV) infection (CEBVI) of 6 years duration developed an EBV+ T-cell lymphoma. To determine whether the development of the T-cell tumor was linked to EBV, we studied this patient's EBV-specific immune response and her T-cell tumor tissue for evidence of EBV infection. Peripheral blood lymphocytes from this patient were systematically studied for immune function and response to EBV. Tumor tissue was examined for EBV genome and for evidence of EBV replication. This patient failed to develop anti-EBV nuclear antigen (EBNA) antibodies and had decreased mitogen responsiveness. Her T-cells showed a broad suppression of both autologous and allogeneic B-cells, which was coincident with clinical hypoimmunoglobulinemia. A selective cytotoxic T-cell defect toward autologous EBV-infected B lymphoblasts, which could not be corrected by the addition of lymphokine-mediated T-cell help, was also documented. A lymph node biopsy taken 5 years after her clinical presentation revealed lymph node architecture completely effaced by a diffuse CD3+, CD4+, Ia+, CR2+ T-cell lymphoma containing EBNA and linear, replicating EBV DNA. Select CEBVI patients with humoral and combined cellular aberrations in the immune response to EBV may be predisposed to the development of EBV+ T-cell tumors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2168301     DOI: 10.1016/0090-1229(90)90020-q

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  8 in total

1.  Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas.

Authors:  Jingwu Xu; Ali Ahmad; José Menezes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 2.  Lymphoproliferative disease in organ transplant recipients.

Authors:  M A Nalesnik
Journal:  Springer Semin Immunopathol       Date:  1991

3.  Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection.

Authors:  Michiko K Oyoshi; Hiroshi Nagata; Nobuhiro Kimura; Yu Zhang; Ayako Demachi; Toshiro Hara; Hirokazu Kanegane; Yoshinobu Matsuo; Tomohiro Yamaguchi; Tomohiro Morio; Atsuyoshi Hirano; Norio Shimizu; Kohtaro Yamamoto
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  Characterization of hu-PBL-SCID mice with high human immunoglobulin serum levels and graft-versus-host disease.

Authors:  M A Duchosal; S A Eming; P J McConahey; F J Dixon
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

5.  Fulminant EBV-driven CD8 T-cell lymphoproliferative disorder following primary acute EBV infection: a unique spectrum of T-cell malignancy.

Authors:  Ken H Young; Dahua Zhang; Jeffery T Malik; Eliot C Williams
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

6.  Intact antigen presentation for Epstein-Barr virus (EBV)-specific CTL by a lymphoblastoid cell line established from a patient with severe chronic active EBV infection.

Authors:  H Kimura; I Tsuge; S Imai; M Yamamoto; K Kuzushima; T Osato; T Morishima
Journal:  Med Microbiol Immunol       Date:  1995-08       Impact factor: 3.402

7.  A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas.

Authors:  S J Hamilton-Dutoit; G Pallesen
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

8.  Presence of the diffuse early antigen of Epstein-Barr virus in lymphomas and lymphoproliferative disorders.

Authors:  B Z Katz; U Saini
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.